Brevan Howard Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Brevan Howard Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.75M	Buy	17,622 +14,470	+459%	+$6.41M	0.06%	202
2026 Q1	$1.41M	Buy	+3,152	New	+$1.47M	0.01%	725
2025 Q1	–	Sell	-7,270	Closed	-$2.93M	–	1492
2024 Q4	$2.93M	Sell	7,270 -119	-2%	-$55.2K	0.02%	215
2024 Q3	$3.44M	Buy	7,389 +2,965	+67%	+$1.42M	0.02%	169
2024 Q2	$2.07M	Sell	4,424 -208	-4%	-$90.3K	0.02%	205
2024 Q1	$1.94M	Sell	4,632 -198	-4%	-$83.7K	0.02%	157
2023 Q4	$1.97M	Buy	4,830 +3,303	+216%	+$1.22M	0.02%	126
2023 Q3	$531K	Buy	+1,527	New	+$534K	0.01%	162

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Brevan Howard Capital Management's VRTX Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 459% in Q2 2026, buying an estimated $6.41M and bringing the position to 17,622 shares worth $8.75M. The position accounts for 0.06% of the portfolio, ranked #202.

Brevan Howard Capital Management first reported a position in VRTX in Q3 2023 and has held it in 8 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Brevan Howard Capital Management held 17,622 shares of Vertex Pharmaceuticals worth $8.75M as of Q2 2026.
Brevan Howard Capital Management bought 14,470 Vertex Pharmaceuticals shares in Q2 2026, an estimated $6.41M.
Vertex Pharmaceuticals made up 0.06% of Brevan Howard Capital Management's portfolio in Q2 2026, its #202 holding.
Brevan Howard Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.